First Phase III study of Sanofi Pasteur dengue vaccine candidate achieves primary endpoint


Monday, 28 Apr 2014 01:02am EDT 

Sanofi SA:Vaccines division Sanofi Pasteur announces that first of two pivotal Phase III efficacy studies with its dengue vaccine candidate has achieved its primary clinical endpoint.Efficacy study showed reduction of 56 pct of dengue disease cases.Initial safety data consistent with safety profile observed in previous studies.Full analysis of data to be undertaken in subsequent weeks and reviewed by external experts prior to disclosure at upcoming international scientific congress and publication in a peer-reviewed journal.Results to be further complemented by results in Q3 2014 from second study being conducted in Latin America, including more than 20,000 volunteers from Brazil, Colombia, Honduras, Mexico and Puerto Rico. 

Company Quote

75.34
0.35 +0.47%
3:40am EST